01.27.15
BioTime has received 14 new patents worldwide The patents cover a range of the company’s and its subsidiaries’ core technologies, and exist in the field of pluripotent stem cell technology for human therapeutic application, otherwise known as regenerative medicine.
Pluripotent stem cells are cells capable of indefinite expansion and then differentiation into any of the cell types in the human body. Examples of pluripotent stem cells are human embryonic stem cells (HES) and induced pluripotent stem (IPS) cells. These stem cells potentially offer a new technology platform for the manufacture of a wide array of cell types designed to be transplanted into the body to restore healthy tissue function.
“BioTime and its subsidiaries are focused on developing and commercializing a broad portfolio of innovative cellular therapeutics and diagnostic products, while also continuing to build value in other ways, such as through the addition of new patents to our industry-leading intellectual property estate,” said Michael D. West, Ph.D., CEO of BioTime. “We are making significant strides in patenting our core platform of pluripotent stem cell technology and strengthening our competitive position in regenerative medicine. For the first time in history, pluripotent stem cells offer a means of manufacturing previously rare and valuable human cell types in a cost-effective manner and on an industrial scale. We plan to utilize our strengthened patent position to drive value for our shareholders as the field of regenerative medicine begins to address the large and growing markets associated with chronic and age-related degenerative disease.”
One of the patents issued in Canada and China cover stem cells that treated with specific growth factors and differentiation conditions to manufacture beating heart muscle cells. Another issued in South Korea covers methods for using pluripotent stem cell technology for inducing immune tolerance of cells transplanted into a patient. Two of the patents claim methods for growing cartilage cells. Two of the patents were issued in the United States.
Pluripotent stem cells are cells capable of indefinite expansion and then differentiation into any of the cell types in the human body. Examples of pluripotent stem cells are human embryonic stem cells (HES) and induced pluripotent stem (IPS) cells. These stem cells potentially offer a new technology platform for the manufacture of a wide array of cell types designed to be transplanted into the body to restore healthy tissue function.
“BioTime and its subsidiaries are focused on developing and commercializing a broad portfolio of innovative cellular therapeutics and diagnostic products, while also continuing to build value in other ways, such as through the addition of new patents to our industry-leading intellectual property estate,” said Michael D. West, Ph.D., CEO of BioTime. “We are making significant strides in patenting our core platform of pluripotent stem cell technology and strengthening our competitive position in regenerative medicine. For the first time in history, pluripotent stem cells offer a means of manufacturing previously rare and valuable human cell types in a cost-effective manner and on an industrial scale. We plan to utilize our strengthened patent position to drive value for our shareholders as the field of regenerative medicine begins to address the large and growing markets associated with chronic and age-related degenerative disease.”
One of the patents issued in Canada and China cover stem cells that treated with specific growth factors and differentiation conditions to manufacture beating heart muscle cells. Another issued in South Korea covers methods for using pluripotent stem cell technology for inducing immune tolerance of cells transplanted into a patient. Two of the patents claim methods for growing cartilage cells. Two of the patents were issued in the United States.